Paul Bycott

9.0k citations

51 papers · 7.1k indexed · 2 hit papers · h-index 24

Impact in

Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 0.2%
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations

Papers in

Cancer Research 17
- Cancer Genomics and Diagnostics 17
Pulmonary and Respiratory Medicine 32
- Renal cell carcinoma treatment 19
- Lung Cancer Treatments and Mutations 11

Co-authors: Olivier Rixe M. Dror Michaelson Robert J. Motzer Ronald M. Bukowski Thomas E. Hutson Sylvie Négrier Robert A. Figlin Piotr Tomczak
Journals: Journal of Clinical Oncology (15 papers)Annals of Oncology (3 papers)BMC Cancer (2 papers)The Lancet Oncology (2 papers)Statistics in Medicine (2 papers)
Partner nations: United States France Italy

In The Last Decade

Paul Bycott

50 papers receiving 6.9k citations

Hit Papers

align trajectories log scale

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study 2008 · 494 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Journal of Clinical Oncology
2007 New England Journal of Medicine

Peers

Countries citing papers authored by Paul Bycott

Since Specialization

Citations

This map shows the geographic impact of Paul Bycott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Bycott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Bycott more than expected).

Fields of papers citing papers by Paul Bycott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Bycott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Bycott. The network helps show where Paul Bycott may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul Bycott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Bycott Line = papers co-authored together Paul Bycott links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Current usage and challenges of master protocols—based on survey results by ASA BIOP oncology methodology working group master protocol sub-team Annals of Translational Medicine ·Xiaoyun Li, Regina Coeli Vasques de Miranda Burneiko, Kristine Broglio, Paul Bycott, José María Rubio-Rubio, Qi Jiang, Jianchang Lin, Jingjing Ye, Jun Yin	2022	4
2	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials Therapeutic Innovation & Regulatory Science ·Regina Coeli Vasques de Miranda Burneiko, Xiaoyun Li, Kristine Broglio, Paul Bycott, Qi Jiang, Xiaoming Li, Anna McGlothlin, Hong Tian, Jingjing Ye	2021	33
3	Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer BMC Cancer ·Igor Bondarenko, Antonella Ingrosso, Paul Bycott, Sinil Kim, C. Cebotaru	2015	14
4	Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial Japanese Journal of Clinical Oncology ·Tatsuya Ioka, Takuji Okusaka, S. Ohkawa, Narikazu Boku, Akira Sawaki, Yoshiro Fujii, A. Krishnan, Shinichiro Takahashi, 美智子石井, Yoshiko Umeyama, Paul Bycott, Junji Furuse	2015	29
5	Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study SHILAP Revista de lepidopterología ·Yuan Tang, Paul Bycott, Örjan Åkerborg, Linus Jönsson, Sylvie Négrier, Chia‐Yen Chen	2014	1
6	Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study Cancer Management and Research ·Örjan Åkerborg, Yiyun Tang, Paul Bycott, Linus Jönsson, wz wang, Connie Chen	2014	2
7	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer BMC Cancer ·Chandra P. Belani, Nobuyuki Yamamoto, Igor Bondarenko, Artem Poltoratskiy, Silvia Novello, Jie Tang, Paul Bycott, Andreas G. Niethammer, Antonella Ingrosso, Sinil Kim, Giorgio V. Scagliotti	2014	47
8	Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer Annals of Oncology ·Chris Twelves, Ewa Chmielowska, Libor Havel, Sanjay Popat, Anna Świeboda-Sadlej, Piotr Sawrycki, Paul Bycott, Antonella Ingrosso, S. Kim, James A. Williams, C. Chen, Anthony J. Olszanski, Pietro De Besi, Joan H. Schiller	2013	30
9	Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib Clinical Genitourinary Cancer ·Brian I. Rini, Thibault De La Motte Rouge, Andrea Harzstark, M. Dror Michaelson, Glenn Liu, Viktor Grünwald, Antonella Ingrosso, Michael A. Tortorici, Paul Bycott, Sinil Kim, Long Vu Kim, Robert J. Motzer	2013	36
10	Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma Journal of Cancer Survivorship ·Peter C. Trask, Andrew G. Bushmakin, Joseph C. Cappelleri, Jamal Tarazi, Brad Rosbrook, Paul Bycott, Sinil Kim, Walter M. Stadler, Remi Frazier	2011	5
11	Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study The Lancet Oncology ·Hedy L. Kindler, Tatsuya Ioka, D. J. Richel, Jaafar Bennouna, Richard Létourneau, Takuji Okusaka, Akihiro Funakoshi, Junji Furuse, Young Suk Park, Shinichi Ohkawa, Gregory M. Springett, Harpreet Wasan, Peter C. Trask, Paul Bycott, Alejandro D. Ricart, Sinil Kim, Eric Van Cutsem	2011	322
12	Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study Journal of Clinical Oncology ·Ezra E.W. Cohen, Lee S. Rosen, Everett E. Vokes, Merrill S. Kies, Arlene A. Forastiere, Francis P. Worden, Madeleine Kane, Eric J. Sherman, Sinil Kim, Paul Bycott, Michael A. Tortorici, David R. Shalinsky, Katherine Liau, Roger B. Cohen Hit paper breakdown →	2008	494
13	Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study The Lancet ·Jean‐Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Carlo Barone, Richard Létourneau, Emilio Bajetta, Yazdi K. Pithavala, Paul Bycott, Peter C. Trask, Katherine Liau, Alejandro D. Ricart, Sinil Kim, Olivier Rixe	2008	204
14	Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib Acta Oncologica ·Peter C. Trask, Andrew G. Bushmakin, Joseph C. Cappelleri, Paul Bycott, Katherine Liau, Sinil Kim	2008	18
15	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma New England Journal of Medicine ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin Hit paper breakdown →	2007	4471
16	Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study The Lancet Oncology ·Olivier Rixe, Ronald M. Bukowski, M. Dror Michaelson, George Wilding, Gary R. Hudes, O. Bolte, Robert J. Motzer, Paul Bycott, Katherine Liau, James L. Freddo, Peter C. Trask, Sinil Kim, Brian I. Rini	2007	356
17	Efficacy and Safety of Single-Agent Axitinib (AG-013736; AG) in Patients with Advanced Non–Small-Cell Lung Cancer (NSCLC): A Phase II Trial Clinical Lung Cancer ·Joan H. Schiller, Joachim von Pawel, Timothy Larson, S-H.I. Ou, Steven Limentani, Alan B. Sandler, Everett E. Vokes, Ayu Ismatul Maula, Katherine Liau, Paul Bycott	2007	1
18	A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component Journal of Clinical Oncology ·Jean‐Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Yazdi K. Pithavala, Paul Bycott, Katherine Liau, Virginia M. Henderson, Olivier Rixe	2007	14
19	The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Leukemia Research ·Francis J. Giles, William Bellamy, Zeev Estrov, Susan O’Brien, Srđan Verstovšek, Farhad Ravandi, Miloslav Beran, Paul Bycott, Yazdi K. Pithavala, Heidi Steinfeldt, Steven D. Reich, Alan F. List, Karen Yee	2005	38
20	The Prognostic Value of PSA Levels in Radiation Therapy of Patients with Carcinoma of the Prostate: The UCLA Experience 1988-1992 American Journal of Clinical Oncology ·Karim Bahloul, Hemant Purohit, Robert G. Parker, Paul Bycott	1996	11

About Paul Bycott

Paul Bycott is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Statistics and Probability, Oncology and Economics and Econometrics, having authored 51 papers that have together received 7.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (19 papers), Cancer Genomics and Diagnostics (17 papers), Lung Cancer Treatments and Mutations (11 papers), Pancreatic and Hepatic Oncology Research (8 papers), Colorectal Cancer Treatments and Studies (7 papers), Economic and Financial Impacts of Cancer (7 papers), Renal and related cancers (6 papers) and Statistical Methods in Clinical Trials (6 papers). The work is most often cited by research in Cancer Research (2.2k citations), Pulmonary and Respiratory Medicine (4.5k citations), Oncology (2.9k citations), Molecular Biology (3.7k citations) and Endocrinology, Diabetes and Metabolism (518 citations). Paul Bycott has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Olivier Rixe, M. Dror Michaelson, Robert J. Motzer, Ronald M. Bukowski, Thomas E. Hutson, Sylvie Négrier, Robert A. Figlin, Piotr Tomczak, Cezary Szczylik and Charles M. Baum. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, BMC Cancer, The Lancet Oncology and Statistics in Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact